查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949469

鷹架技術市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、疾病類型、應用、最終用戶、地區和競爭格局分類，2021-2031年）

Scaffold Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Disease Type, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球鷹架技術市場預計將從 2025 年的 22.2 億美元成長到 2031 年的 35.2 億美元，複合年成長率為 7.99%。

支架技術能夠建構多孔的3D結構，模擬天然細胞外基質，為再生醫學和組織工程中的細胞黏附、增殖和分化提供基礎。推動這項技術發展的關鍵因素包括供體器官的嚴重短缺，以及日益成長的減少藥物研發中動物試驗的倫理和監管要求，這兩方面都促使人們迫切需要有效的生物替代物。美國衛生資源與服務管理局 (HRSA) 的報告凸顯了這一緊迫性：到 2024 年，美國國家移植等待名單上的候選人將超過 10.3 萬人，這表明生物工程組織替代品在商業性和臨床方面有著巨大的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 22.2億美元
市場規模：2031年 35.2億美元
複合年成長率：2026-2031年 7.99%
成長最快的細分市場 水凝膠
最大的市場 北美洲

儘管市場成長前景良好，但仍面臨一項重大挑戰：支架製造和材料表徵缺乏標準化。生物材料固有的天然變異性，加上難以在商業規模上持續複製其複雜的微觀結構，使得批次間一致性難以保證。缺乏成熟的製造通訊協定阻礙了監管核准流程，並延緩了基於支架的創新成果從實驗室走向廣泛臨床應用的進程。

市場促進因素

3D生物列印和生物材料的創新正在改變全球支架技術市場，使建造先前無法實現的複雜、大規模組織結構成為可能。先進生物墨水與高解析度列印系統的結合，能夠精準定位細胞和基質成分，有效解決厚組織血管化難題。 2024年6月，CollPlant Biotechnologies宣布利用其專有的重組人類膠原蛋白生物墨水生產出200cc商業規模的再生乳房植入，這一重大突破意義非凡。該成就表明，該行業從實驗性微組織到臨床應用器官類似物的規模化生產能力日益增強，加速了基於支架的塑膠重組和治療解決方案的研發進程。

同時，研發投入的不斷增加正成為推動這些技術走向臨床應用的資金引擎。來自公共和私營部門的資金日益集中於那些利用支架平台滿足高度未滿足醫療需求的公司，例如癌症治療和神經退化性疾病。加州再生醫學研究所2024年度報告凸顯了這一領域的強勁勢頭，報告指出，Neurona Therapeutics公司籌集了1.2億美元，用於推進依賴複雜遞送系統的細胞療法。這筆資金的湧入主要是為了因應慢性疾病的日益增加。例如，美國癌症協會在2024年1月預測，美國新增癌症病例數將首次超過200萬，促使投資人加強對能夠改善疾病建模和組織修復的支架解決方案的支持。

市場挑戰

支架製造和材料表徵缺乏標準化通訊協定，嚴重阻礙了全球支架技術市場的發展。這個問題源自於生物材料固有的變異性以及大規模複製精確微觀結構的技術複雜性。因此，製造商難以確保批次間的一致性，也難以建立大規模生產所需的統一流程。由於缺乏標準化方法，企業在將成功的實驗室原型轉化為商業性化產品的過程中面臨瓶頸，導致供應鏈停滯，而臨床上對組織替代的需求卻十分迫切。

這種異質性直接阻礙了監管核准和市場准入，因為監管機構要求提供嚴格的可重複性證明以確保病人安全。無法證明生產結果的一致性會導致商業化進程顯著延遲，並限制已通過核准治療方法的廣泛應用。因此，規模化生產的困難阻礙了大多數創新在臨床實踐中的廣泛應用。再生醫學聯盟報告稱，到2025年，全球先進療法領域75%的收入將由不到10種產品創造。這種高度的收入集中度凸顯了生產壁壘和缺乏標準化如何持續限制整體市場成長潛力。

市場趨勢

將人工智慧 (AI) 應用於支架設計正在革新整個產業，因為它能夠開發出更符合生理規律的生物結構。與傳統方法不同，AI 演算法可以在生產前預測細胞與材料的相互作用並最佳化內部孔隙率，從而顯著減少組織工程中的試驗。 Aspect Biosystems 公司成功完成資金籌措，進一步開發其模式識別技術，凸顯了這種計算方法的價值。正如該公司在 2025 年 1 月的新聞稿中所述，該公司在 B 輪資金籌措中籌集了 1.15 億美元，用於擴展其平台。該平台利用 AI 驅動的設計工具來創建生物列印組織療法。

同時，對能夠最大限度減少免疫排斥並促進自然重塑的構建體的需求日益成長，促使脫細胞細胞外基質（dECM）生物支架作為合成聚合物的更優替代品得到廣泛應用。這些生物支架保留了觸發細胞訊號傳導的天然生化訊號，從而促進與宿主的快速整合。這一趨勢最終促成了美國食品藥物管理局（FDA）於2024年12月核准Humacyte公司的Symvess上市，這標誌著無細胞組織商業性可行性的一個重要監管里程碑。這種基於dECM的血管移植物核准，代表著生物工程人體組織臨床應用的突破。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球鷹架技術市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（水凝膠{創傷治療、3D生物列印、免疫調節}、聚合物支架、微圖案化表面微孔盤、奈米纖維支架）
    • 依疾病類型（整形外科、肌肉骨骼和脊椎、癌症、皮膚和覆蓋組織、牙科、心血管、神經科、泌尿系統、婦科、其他）
    • 依應用領域（幹細胞療法、再生醫學/組織工程、藥物研發等）
    • 依最終用戶（生技/製藥公司、研究機構、醫院/診斷中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美鷹架技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲支架技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區鷹架技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東與非洲鷹架技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲鷹架技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球鷹架技術市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Tecan Group Ltd.
  • REPROCELL Inc.
  • 3D Biotek, LLC
  • Becton, Dickinson, and Company
  • Medtronic plc
  • Xanofi, Inc.
  • Molecular Matrix, Inc.
  • Matricel GmbH
  • PELOBiotech GmbH
  • Corning Incorporated

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23767

The Global Scaffold Technology Market is projected to expand from USD 2.22 Billion in 2025 to USD 3.52 Billion by 2031, registering a CAGR of 7.99%. Scaffold technology involves the creation of porous three-dimensional structures that simulate the natural extracellular matrix, acting as a template to facilitate cell adhesion, proliferation, and differentiation for regenerative medicine and tissue engineering. The primary catalysts for this growth include the severe shortage of donor organs and increasing ethical and regulatory mandates to reduce animal testing in drug development, both of which drive the need for effective biological substitutes. Highlighting this urgency, the Health Resources and Services Administration reported in 2024 that over 103,000 candidates were on the U.S. national transplant waiting list, emphasizing the critical commercial and clinical demand for bioengineered tissue alternatives.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.22 Billion
Market Size 2031USD 3.52 Billion
CAGR 2026-20317.99%
Fastest Growing SegmentHydrogels
Largest MarketNorth America

Despite this positive growth outlook, the market contends with a major hurdle regarding the absence of standardization in scaffold manufacturing and material characterization. The natural variability inherent in biological materials, combined with the difficulty of consistently replicating intricate micro-architectures at a commercial scale, creates challenges in maintaining batch-to-batch uniformity. This lack of established manufacturing protocols hinders the regulatory approval pathway and delays the progression of scaffold-based innovations from research laboratories to widespread clinical application.

Market Driver

Innovations in 3D Bioprinting and Biomaterials are transforming the Global Scaffold Technology Market by allowing for the creation of complex, large-scale tissue constructs that were previously unachievable. The combination of advanced bioinks with high-resolution printing systems enables the precise placement of cells and matrix components, effectively solving the issue of vascularization in thick tissues. A significant breakthrough was marked in June 2024 when CollPlant Biotechnologies announced the production of 200cc commercial-scale regenerative breast implants using its proprietary recombinant human collagen bioinks. This achievement highlights the industry's growing capacity to scale up from experimental micro-tissues to clinically relevant organ analogues, accelerating the timeline for scaffold-based reconstructive and therapeutic solutions.

Simultaneously, rising investments in research and development act as the financial engine driving these technologies toward clinical use. Funding from both public and private sectors is increasingly targeted at companies employing scaffold platforms to address high unmet medical needs, such as oncology and neurodegenerative diseases. The sector's robustness was highlighted in the California Institute for Regenerative Medicine's 2024 Annual Report, which noted that Neurona Therapeutics raised $120 million to further cell therapies dependent on complex delivery systems. This influx of capital is largely a response to the growing prevalence of chronic diseases; for instance, the American Cancer Society projected in January 2024 that new cancer diagnoses in the U.S. would exceed 2 million for the first time, prompting investors to support scaffold solutions that offer improved disease modeling and tissue repair.

Market Challenge

The absence of standardized protocols for scaffold fabrication and material characterization poses a significant barrier to the growth of the Global Scaffold Technology Market. This issue stems from the inherent variability of biological materials and the technical complexity involved in reproducing precise micro-architectures at a commercial scale. As a result, manufacturers struggle to guarantee batch-to-batch consistency, making it difficult to establish the uniform processes required for mass production. Without these standardized methods, companies face a bottleneck in transitioning successful laboratory prototypes into commercially viable products, stalling the supply chain despite the pressing clinical need for tissue replacements.

This inconsistency directly impedes regulatory approval and market access, as agencies demand rigorous proof of reproducibility to ensure patient safety. The inability to demonstrate consistent manufacturing results causes significant delays in commercialization and restricts the availability of approved therapies. Consequently, scaling difficulties prevent most innovations from reaching widespread clinical adoption. In 2025, the Alliance for Regenerative Medicine reported that 75 percent of global revenue in the advanced therapy sector is generated by fewer than 10 products. This high concentration of revenue underscores how manufacturing hurdles and the lack of standardization continue to limit the broader market from realizing its full growth potential.

Market Trends

The incorporation of Artificial Intelligence into scaffold structural design is revolutionizing the industry by enabling the development of bio-architectures with greater physiological accuracy. Unlike conventional methods, AI algorithms can now predict cell-material interactions and optimize internal porosities prior to production, drastically reducing trial-and-error in tissue engineering. The value of this computational approach was confirmed when Aspect Biosystems secured significant funding to further its pattern-recognition technologies. As detailed in a January 2025 press release, the company raised $115 million in Series B financing to expand its platform, which utilizes AI-driven design tools for creating bioprinted tissue therapeutics.

Concurrently, there is a growing shift toward using Decellularized Extracellular Matrix (dECM) bio-scaffolds as a superior alternative to synthetic polymers, driven by the need for constructs that minimize immune rejection and support natural remodeling. These biological scaffolds preserve native biochemical cues that trigger cellular signaling, facilitating faster integration with the host body. This trend achieved a major regulatory milestone regarding the commercial viability of acellular tissues when the U.S. Food and Drug Administration approved Humacyte's Symvess in December 2024. This approval of a dECM-based vascular conduit represents a pivotal advancement in the clinical application of bioengineered human tissues.

Key Market Players

  • Tecan Group Ltd.
  • REPROCELL Inc.
  • 3D Biotek, LLC
  • Becton, Dickinson, and Company
  • Medtronic plc
  • Xanofi, Inc.
  • Molecular Matrix, Inc.
  • Matricel GmbH
  • PELOBiotech GmbH
  • Corning Incorporated

Report Scope

In this report, the Global Scaffold Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Scaffold Technology Market, By Type

  • Hydrogels {Wound Healing, 3D Bioprinting, Immunomodulation}
  • Polymeric Scaffolds
  • Micropatterned Surface Microplates
  • Nanofiber Based Scaffolds

Scaffold Technology Market, By Disease Type

  • Orthopedics
  • Musculoskeletal & Spine
  • Cancer
  • Skin & Integumentary
  • Dental
  • Cardiology & Vascular
  • Neurology
  • Urology
  • Gynecology
  • Others

Scaffold Technology Market, By Application

  • Stem Cell Therapy
  • Regenerative Medicine & Tissue Engineering
  • Drug Discovery
  • Others

Scaffold Technology Market, By End User

  • Biotechnology & Pharmaceuticals Organizations
  • Research Laboratories & Institutes
  • Hospitals & Diagnostic Centers
  • Others

Scaffold Technology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Scaffold Technology Market.

Available Customizations:

Global Scaffold Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Scaffold Technology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Hydrogels {Wound Healing, 3D Bioprinting, Immunomodulation}, Polymeric Scaffolds, Micropatterned Surface Microplates, Nanofiber Based Scaffolds)
    • 5.2.2. By Disease Type (Orthopedics, Musculoskeletal & Spine, Cancer, Skin & Integumentary, Dental, Cardiology & Vascular, Neurology, Urology, Gynecology, Others)
    • 5.2.3. By Application (Stem Cell Therapy, Regenerative Medicine & Tissue Engineering, Drug Discovery, Others)
    • 5.2.4. By End User (Biotechnology & Pharmaceuticals Organizations, Research Laboratories & Institutes, Hospitals & Diagnostic Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Scaffold Technology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Disease Type
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Scaffold Technology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Disease Type
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Scaffold Technology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Disease Type
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Scaffold Technology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Disease Type
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Scaffold Technology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Disease Type
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Scaffold Technology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Scaffold Technology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Scaffold Technology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Scaffold Technology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Disease Type
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Scaffold Technology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Disease Type
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Scaffold Technology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Disease Type
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Scaffold Technology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Scaffold Technology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Scaffold Technology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Scaffold Technology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Scaffold Technology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Scaffold Technology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Disease Type
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Scaffold Technology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Disease Type
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Scaffold Technology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Disease Type
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Scaffold Technology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Disease Type
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Scaffold Technology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Disease Type
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Scaffold Technology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Scaffold Technology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Scaffold Technology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Scaffold Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Tecan Group Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. REPROCELL Inc.
  • 15.3. 3D Biotek, LLC
  • 15.4. Becton, Dickinson, and Company
  • 15.5. Medtronic plc
  • 15.6. Xanofi, Inc.
  • 15.7. Molecular Matrix, Inc.
  • 15.8. Matricel GmbH
  • 15.9. PELOBiotech GmbH
  • 15.10. Corning Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer